Press Releases

UK biotech sector enjoys record year of investment

A record £3 billion has been raised by the UK biotech and life science sector in the first three quarters of 2021, according to new data released today by the BioIndustry Association (BIA) and Clarivate. With £576m raised between June and the end of August, fundraising in 2021 has already surpassed the previous record year of 2020, when £2.8 billion was raised, with another three months of the year left to go.

BIA launches Comprehensive Spending Review priorities to turn UK into a life sciences superpower

The BioIndustry Association (BIA) has today launched its recommendations for the Comprehensive Spending Review, the report ‘Becoming a life sciences superpower’, explains the policies that the Government can implement to turbo charge growth in the innovative UK biotech and life sciences sector.

New report reveals strength of the UK’s thriving genomics sector

The BioIndustry Association (BIA), the Wellcome Sanger Institute and Medicines Discovery Catapult (MDC) have today launched Genomics Nation, showcasing the strength, breadth and opportunity of the UK’s genomics sector for investors, patients and the UK economy.

New investors drawn to UK biotech as global appetite for innovation continues

New analysis shows that biotech shares on the London Stock Exchange continued to out-perform the wider market in the first half of 2021 as international investors were drawn to the UK’s strong science and high-quality companies.

 

Member News

BioPharma Dynamics unveil brand new cleanroom facility to support the Life Sciences Industry

BioPharma Dynamics, a leading life sciences solution provider, proudly announce the opening of their new ISO Class 7 cleanroom facility located at new headquarters in Salford, Greater Manchester.

Enesi Pharma Enters Agreement with National Institutes of Health to Evaluate ImplaVax®-enabled Flu Vaccines

OXFORD, UK – 19 October 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies, has entered into an agreement with the US National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to test a novel ImplaVax® enabled pandemic flu vaccine.

EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs

Provides roadmap to commercial agreement based on shared objective to secure patient access to innovative and cost-effective cancer medicines   Agreement with one of the largest public healthcare systems globally demonstrates EQRx’s commitment to offering new medicines to patients at radically lower prices EQRx’s lead cancer programs, aumolertinib and sugemalimab, have received Innovation Passport designations through the Innovative Licensing and Access Pathway (ILAP)

Scancell expands its R&D capabilities with new facilities at The Oxford Science Park

Oxford, UK, 19 October 2021 – Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, has expanded its R&D capabilities by taking new laboratory and office space in the Bellhouse Building at The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies.

 

BIA blog

Guest blog: 2021 Health Trends: Speed & Scale in the Great Disruption

In early 2020, I was in a virtual green room at one of our industry’s major conferences. As we were preparing for a panel discussion, the host asked me: so that 2020 Trends report, looks like you missed a pretty big one, right?

CEO Update | 19 October 2021

Next week the Chancellor will deliver the Comprehensive Spending Review and Budget. We are working hard to get our sector’s needs across to Ministers and Treasury officials.  In a final push this week we are coordinating letters from BIA members to the Chancellor calling on him to increase Innovate UK’s budget, plus protecting and expanding R&D tax credits. Please help by sending your own short email to the Chancellor, explaining how these things have helped your business, both to public.enquiries@hmtreasury.gov.uk and  Martin Turner our Head of Policy and Public Affairs who is organising our efforts.

CEO Update | 11 October 2021

A record £3 billion has been raised by our sector in the first three quarters of 2021 according to our latest data released today with Clarivate. With £576m raised between June and the end of August, fundraising in 2021 has already surpassed the previous record year of 2020, when £2.8 billion was raised, with another three months of the year left to go.

CEO Update | 04 October 2021

Last week saw the public listing of BIA member Oxford Nanopore on the London Stock Exchange. As the Financial Times reported ‘Shares in Oxford Nanopore surged more than 40 per cent after its initial public offering in London. By market close on Thursday the stock was 43 per cent higher at 607p, giving it a market capitalisation of £4.8bn, up £1.3bn. It is the eighth-biggest listing in London this year and the third-largest biotech float globally in 2021.’

 

Our publications

Please find a selection of featured BIA publications below. To see our full publications library, click here

Influencing and shaping our sector | BIA update: October 2019 - January 2020

This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from October 2019 to January 2020.

Global and growing - UK biotech financing in 2019

New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019.

UK life sciences: Catalysing investment and growth

This updated interim report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector.

BIA biotech manifesto 2019

The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.